Literature DB >> 26661629

Esomeprazole induced galactorrhea: a novel side effect.

Nirav Pipaliya1, Dattatray Solanke2, Chetan Rathi2, Ruchir Patel2, Meghraj Ingle2, Prabha Sawant2.   

Abstract

Proton pump inhibitors (PPIs) are one of the most frequently prescribed medications across the globe. Esomeprazole is the S-isomer of omeprazole, and it is currently the most widely prescribed PPI. The safety profile of esomeprazole is extremely favorable with only minor side effects, like headache and diarrhea, that are encountered in day to day practice. We report a case of a young female with symptoms of gastroesophageal reflux disease who developed galactorrhea after starting esomeprazole therapy. Resolution of galactorrhea after stopping the drug and self-rechallenge by the patient herself with reappearance of galactorrhea confirmed the culprit to be esomeprazole only. We postulate that esomeprazole may have a mild inhibitory effect on CYP3A4, which leads to decreased metabolism of estrogen, thereby increasing serum estrogen levels. Estrogen causes stimulation and production of prolactin release, which results in development of galactorrhea. This is the first case of esomeprazole induced galactorrhea, to the best of our knowledge.

Entities:  

Keywords:  Esomeprazole; Galactorrhea; Proton pump inhibitors

Mesh:

Substances:

Year:  2015        PMID: 26661629     DOI: 10.1007/s12328-015-0622-7

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  16 in total

1.  Hyperprolactinaemia induced by proton pump inhibitor.

Authors:  Abdul Jabbar; Rabbia Khan; Syed Nadir Farrukh
Journal:  J Pak Med Assoc       Date:  2010-08       Impact factor: 0.781

2.  Estrogen regulation of prolactin gene transcription in vivo: paradoxical effects of 17 beta-estradiol dose.

Authors:  J D Shull; J Gorski
Journal:  Endocrinology       Date:  1989-01       Impact factor: 4.736

3.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.

Authors:  Donald O Castell; Peter J Kahrilas; Joel E Richter; Nimish B Vakil; David A Johnson; Seth Zuckerman; Wendy Skammer; Jeffrey G Levine
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

4.  Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects.

Authors:  Uriel Halbreich; Linda S Kahn
Journal:  J Psychiatr Pract       Date:  2003-09       Impact factor: 1.325

5.  Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.

Authors:  J E Richter; P J Kahrilas; J Johanson; P Maton; J R Breiter; C Hwang; V Marino; B Hamelin; J G Levine
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

6.  [Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database].

Authors:  Abir Petit; Dorothée Piednoir; Marie-Laure Germain; Thierry Trenque
Journal:  Therapie       Date:  2003 Mar-Apr       Impact factor: 2.070

7.  Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.

Authors:  Miranda Davies; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote.

Authors:  Beth Rosenshein; David A Flockhart; Herbert Ho
Journal:  Am J Med Sci       Date:  2004-05       Impact factor: 2.378

Review 9.  Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.

Authors:  U Halbreich; B J Kinon; J A Gilmore; L S Kahn
Journal:  Psychoneuroendocrinology       Date:  2003-01       Impact factor: 4.905

Review 10.  Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole.

Authors:  T Andersson; M Hassan-Alin; G Hasselgren; K Röhss
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

View more
  5 in total

1.  Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.

Authors:  Shan Jing; Yue Zhu; Wenfang Liu; Kexu Yang; Lili Hu; Dan Deng; Chunyan Lu; Yang Lin
Journal:  Adv Ther       Date:  2021-02-11       Impact factor: 3.845

Review 2.  ANTI-ULCEROGENIC EFFICACY AND MECHANISMS OF EDIBLE AND NATURAL INGREDIENTS IN NSAID-INDUCED ANIMAL MODELS.

Authors:  Weiping Bi; Lizhi Hu; Mao-Qiang Man
Journal:  Afr J Tradit Complement Altern Med       Date:  2017-06-05

3.  Nipple aspirate fluid-A liquid biopsy for diagnosing breast health.

Authors:  Sadr-Ul Shaheed; Catherine Tait; Kyriacos Kyriacou; Joanne Mullarkey; Wayne Burrill; Laurence H Patterson; Richard Linforth; Mohamed Salhab; Chris W Sutton
Journal:  Proteomics Clin Appl       Date:  2017-06-26       Impact factor: 3.494

4.  Ranitidine-induced galactorrhea: Exploring the intricacies.

Authors:  Avik Ray; Ahmad Najmi; Balakrishnan Sadasivam
Journal:  J Family Med Prim Care       Date:  2020-01-28

5.  Omeprazole-induced galactorrhea in kidney transplant patients-a case report.

Authors:  Choki Dorji; Farruk Ahammed Robin; Kesara Na-Bangchang
Journal:  J Med Case Rep       Date:  2022-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.